Ignite Creation Date:
2025-12-25 @ 3:28 AM
Ignite Modification Date:
2026-01-12 @ 4:26 AM
Study NCT ID:
NCT07244705
Status:
RECRUITING
Last Update Posted:
2025-11-24
First Post:
2025-11-10
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRC
Sponsor:
Anbogen Therapeutics, Inc.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2025-11
Start Date Type:
ESTIMATED
Primary Completion Date:
2028-04
Primary Completion Date Type:
ESTIMATED
Completion Date:
2028-07
Completion Date Type:
ESTIMATED
First Submit Date:
2025-11-10
First Submit QC Date:
None
Study First Post Date:
2025-11-24
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-11-17
Last Update Post Date:
2025-11-24
Last Update Post Date Type:
ESTIMATED